"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...
Special Counsel Says ICON CEO Steve Cutler says trial activity has been “impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.” The company ...
"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback